US Food and Drug Administration guidance on emergency use authorization for COVID-19 vaccines should be publicly released to provide regulatory clarity to scientists and researchers and strengthen public confidence in any vaccine authorized by the agency, the Biotechnology Innovation Organization says.
“All new FDA guidance should be finalized and communicated with those on the frontlines developing potential vaccines,” BIO president and...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?